Acute D-serine treatment produces antidepressant-like effects in rodents.

Research suggests that dysfunctional glutamatergic signalling may contribute to depression, a debilitating mood disorder affecting millions of individuals worldwide. Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist, exerts rapid antidepressant effects in approximately 70% of patients. Glutamate evokes the release of D-serine from astrocytes and neurons, which then acts as a co-agonist and binds at the glycine site on the NR1 subunit of NMDA receptors. Several studies have implicated glial deficits as one of the underlying facets of the neurobiology of depression. The present study tested the hypothesis that D-serine modulates behaviours related to depression. The behavioural effects of a single, acute D-serine administration were examined in several rodent tests of antidepressant-like effects, including the forced swim test (FST), the female urine sniffing test (FUST) following serotonin depletion, and the learned helplessness (LH) paradigm. D-serine significantly reduced immobility in the FST without affecting general motor function. Both D-serine and ketamine significantly rescued sexual reward-seeking deficits caused by serotonin depletion in the FUST. Finally, D-serine reversed LH behaviour, as measured by escape latency, number of escapes, and percentage of mice developing LH. Mice lacking NR1 expression in forebrain excitatory neurons exhibited a depression-like phenotype in the same behavioural tests, and did not respond to D-serine treatment. These findings suggest that D-serine produces antidepressant-like effects and support the notion of complex glutamatergic dysfunction in depression. It is unclear whether D-serine has a convergent influence on downstream synaptic plasticity cascades that may yield a similar therapeutic profile to NMDA antagonists like ketamine.

[1]  H. Manji,et al.  Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants , 2012, Molecular Psychiatry.

[2]  Gregory Luke Larkin,et al.  A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. , 2011, The international journal of neuropsychopharmacology.

[3]  Nanxin Li,et al.  Post-weaning chronic social isolation produces profound behavioral dysregulation with decreases in prefrontal cortex synaptic-associated protein expression in female rats , 2011, Physiology & Behavior.

[4]  D. Bennett,et al.  Chronic corticosterone exposure alters postsynaptic protein levels of PSD‐95, NR1, and synaptopodin in the mouse brain , 2011, Synapse.

[5]  H. Manji,et al.  Bax inhibitor 1, a modulator of calcium homeostasis, confers affective resilience , 2011, Brain Research.

[6]  E. Kavalali,et al.  NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses , 2011, Nature.

[7]  A. Mallinger,et al.  Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[8]  Nanxin Li,et al.  Glutamate N-methyl-D-aspartate Receptor Antagonists Rapidly Reverse Behavioral and Synaptic Deficits Caused by Chronic Stress Exposure , 2011, Biological Psychiatry.

[9]  Nanxin Li,et al.  mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists , 2010, Science.

[10]  D. Luckenbaugh,et al.  A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. , 2010, Archives of general psychiatry.

[11]  Daniel C. Javitt,et al.  High dose D-serine in the treatment of schizophrenia , 2010, Schizophrenia Research.

[12]  D. Luckenbaugh,et al.  Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. , 2010, The Journal of clinical psychiatry.

[13]  H. Manji,et al.  Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. , 2010, Journal of affective disorders.

[14]  J. Crawley,et al.  The Female Urine Sniffing Test: A Novel Approach for Assessing Reward-Seeking Behavior in Rodents , 2010, Biological Psychiatry.

[15]  K. Behar,et al.  Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole , 2010, Molecular Psychiatry.

[16]  M. Bowser,et al.  Neuronal release of D‐serine: a physiological pathway controlling extracellular D‐serine concentration , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  K. Nakazawa,et al.  eIF2α Phosphorylation-Dependent Translation in CA1 Pyramidal Cells Impairs Hippocampal Memory Consolidation without Affecting General Translation , 2010, The Journal of Neuroscience.

[18]  G. Tsai,et al.  Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. , 2010, Current pharmaceutical design.

[19]  Yogesh K. Dwivedi,et al.  Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1). , 2009, The international journal of neuropsychopharmacology.

[20]  L. Deutsch,et al.  Pilot controlled trial of D-serine for the treatment of post-traumatic stress disorder. , 2009, The international journal of neuropsychopharmacology.

[21]  Guang Chen,et al.  The neurotrophic and neuroprotective effects of psychotropic agents , 2009, Dialogues in clinical neuroscience.

[22]  R. Duman.  Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression , 2009, Dialogues in clinical neuroscience.

[23]  D. Charney,et al.  Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression , 2009, Biological Psychiatry.

[24]  H. Manji,et al.  Reverse translational strategies for developing animal models of bipolar disorder , 2009, Disease Models & Mechanisms.

[25]  Molly E. Davidson,et al.  d-Serine exposure resulted in gene expression changes implicated in neurodegenerative disorders and neuronal dysfunction in male Fischer 344 rats , 2009, Archives of Toxicology.

[26]  Sarah L. Huszar,et al.  The Behavioral and Neurochemical Effects of a Novel d-Amino Acid Oxidase Inhibitor Compound 8 [4H-Thieno [3,2-b]pyrrole-5-carboxylic Acid] and d-Serine , 2008, Journal of Pharmacology and Experimental Therapeutics.

[27]  M. Krams,et al.  An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder , 2008, Journal of clinical psychopharmacology.

[28]  M. Banasr,et al.  Glial Loss in the Prefrontal Cortex Is Sufficient to Induce Depressive-like Behaviors , 2008, Biological Psychiatry.

[29]  Eric J. Nestler,et al.  The molecular neurobiology of depression , 2008, Nature.

[30]  D. Luckenbaugh,et al.  Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania , 2008, Molecular Psychiatry.

[31]  S. Zisook,et al.  Sequenced Treatment Alternatives to Relieve Depression (STAR*D): lessons learned. , 2008, The Journal of clinical psychiatry.

[32]  B. McEwen,et al.  BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments , 2008, Proceedings of the National Academy of Sciences.

[33]  Carlos A. Zarate,et al.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders , 2008, Nature Reviews Drug Discovery.

[34]  J. Billard.  D-serine signalling as a prominent determinant of neuronal-glial dialogue in the healthy and diseased brain , 2008, Journal of cellular and molecular medicine.

[35]  Guang Chen,et al.  Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors , 2008, Biological Psychiatry.

[36]  S. Noda,et al.  The serine racemase mRNA is predominantly expressed in rat brain neurons. , 2007, Archives of histology and cytology.

[37]  I. Lucki,et al.  Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test , 2007, Psychopharmacology.

[38]  A. Schene,et al.  Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies , 2007, Molecular Psychiatry.

[39]  B. Dean,et al.  Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder , 2007, Brain Research.

[40]  S. Noda,et al.  Expression of the mRNA and protein of serine racemase in primary cultures of rat neurons. , 2006, European Journal of Pharmacology.

[41]  Henry H Yin,et al.  Disrupted motor learning and long-term synaptic plasticity in mice lacking NMDAR1 in the striatum , 2006, Proceedings of the National Academy of Sciences.

[42]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[43]  Lingjiang Li,et al.  CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder , 2006, Brain Research.

[44]  Elena Kartvelishvily,et al.  Neuron-derived D-Serine Release Provides a Novel Means to Activate N-Methyl-D-aspartate Receptors* , 2006, Journal of Biological Chemistry.

[45]  J. Avruch,et al.  Glutamatergic Regulation of the p70S6 Kinase in Primary Mouse Neurons* , 2005, Journal of Biological Chemistry.

[46]  M. Rausch,et al.  The pharmacological stimulation of NMDA receptors via co-agonist site: an fMRI study in the rat brain , 2005, Neuroscience Letters.

[47]  Daniel C. Javitt,et al.  D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia , 2005, Biological Psychiatry.

[48]  T. Toyo’oka,et al.  Simultaneous determination of D- and L-serine in rat brain microdialysis sample using a column-switching HPLC with fluorimetric detection. , 2004, Biomedical chromatography : BMC.

[49]  Gavin P. Reynolds,et al.  The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders , 2004, Neuroscience Letters.

[50]  R. D. L. Garza,et al.  A distinct neurochemical profile in WKY rats at baseline and in response to acute stress: implications for animal models of anxiety and depression , 2004, Brain Research.

[51]  J. Sweatt,et al.  Mitogen-activated protein kinases in synaptic plasticity and memory , 2004, Current Opinion in Neurobiology.

[52]  I. Lucki,et al.  Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[53]  H. Manji,et al.  The Role of the Extracellular Signal-Regulated Kinase Signaling Pathway in Mood Modulation , 2003, The Journal of Neuroscience.

[54]  Eric Vermetten,et al.  Reduced volume of orbitofrontal cortex in major depression , 2002, Biological Psychiatry.

[55]  J. Deakin,et al.  Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses , 2001, Neuroreport.

[56]  R. Kerwin,et al.  Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. , 2001, Archives of general psychiatry.

[57]  Yogesh K. Dwivedi,et al.  Reduced activation and expression of ERK1/2 MAP kinase in the post‐mortem brain of depressed suicide subjects , 2001, Journal of neurochemistry.

[58]  W. Drevets,et al.  The cellular neurobiology of depression , 2001, Nature Medicine.

[59]  P. Haydon.  Glia: listening and talking to the synapse , 2001, Nature Reviews Neuroscience.

[60]  H. Ågren,et al.  Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. , 2000, Archives of general psychiatry.

[61]  D. Linden,et al.  D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[62]  M. Detke,et al.  Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test , 1999, Psychopharmacology.

[63]  J. Price,et al.  Glial reduction in the subgenual prefrontal cortex in mood disorders. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[64]  David J. Anderson,et al.  Subregion- and Cell Type–Restricted Gene Knockout in Mouse Brain , 1996, Cell.

[65]  J. Sweeney,et al.  Attempted Suicide Characteristics and Cerebrospinal Fluid Amine Metabolites in Depressed Inpatients , 1996, Neuropsychopharmacology.

[66]  S. Nakanishi.  Molecular diversity of glutamate receptors and implications for brain function. , 1992, Science.

[67]  S. Maier.  Learned helplessness and animal models of depression , 1984, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[68]  R. Porsolt,et al.  Depression: a new animal model sensitive to antidepressant treatments , 1977, Nature.

[69]  S. Gershon,et al.  Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. , 1976, Archives of general psychiatry.

[70]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[71]  Yogesh K. Dwivedi,et al.  ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf-1 and B-Raf , 2006, Molecular Psychiatry.